Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Alaska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Alaska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Alaska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Max Rabinowitz (NPI 1295770972)

Field	Value
Entity Type	Individual
Organization	Max Rabinowitz
Address	2925 Debarr Rd
City	Anchorage
State	AK
ZIP	99508
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 18, 2006

Payer Source	Total Paid
Medicare	$2M
Medicaid	$0

Key Findings

This provider is heavily oncology-focused with revenue dominated by high-cost immunotherapy drugs: J9271 (19.8K claims, $43 avg paid/claim, $851.4K revenue, 43.2% of this provider's total Medicare revenue) and J9299 (19.4K claims, $24 avg paid/claim, $466.6K revenue, 23.7% of this provider's total Medicare revenue) are the two largest revenue drivers. The presence of other oncology agents such as J9312 (2.3K claims, $64 avg paid/claim, $144.6K revenue, 7.3% of this provider's total Medicare revenue), Q5111 (pegfilgrastim biosimilar) and multiple chemotherapy administration codes (96413, 96401, 96417) confirms an infusion-based oncology practice model rather than primarily clinic-only management. The precomputed concentration statistic shows the top 3 Medicare codes by revenue account for 74.2% of this provider's total Medicare revenue, indicating very high revenue concentration in a small set of oncology drugs.

Revenue concentration is pronounced: the top 3 Medicare codes account for 74.2% of total Medicare receipts, and J9271 alone represents 43.2% of reported Medicare revenue. That concentration signals material exposure to pricing, utilization, and supply dynamics for a few branded oncology drugs, and suggests most Medicare value from this NPI flows through infusion of these agents rather than E/M visits or ancillary services.

Payer mix is effectively single-payer Medicare: Total Medicare revenue is $2M while Total Medicaid revenue is none (no Medicaid billing on file). Because there is no Medicaid activity, any payer-strategy or network negotiation should be evaluated with Medicare as the dominant revenue source and no Medicaid-covered patient volume reported under this NPI.

Competitive standing on major drug codes is mixed: J9271 ranks #406 of 1841 providers nationally (77th percentile; typical, unremarkable volume) and J9299 ranks #174 of 505 providers nationally (65th percentile; typical, unremarkable volume), which together indicate solid but not dominant national participation in checkpoint inhibitor infusion. By contrast, J9312 ranks #228 of 317 providers nationally (28th percentile; typical, unremarkable volume), showing comparatively low national activity on rituximab relative to peers.

Clinical throughput as reflected in office E/M and infusion administration shows higher-than-typical visit-level volume: 99213 has 724 claims, $88 avg paid/claim, $63.7K revenue and ranks #13284 of 457151 providers nationally (97th percentile; notably above typical national volume). Chemotherapy administration code 96413 (534 claims, $117 avg paid/claim, $62.5K revenue) ranks #583 of 7514 providers nationally (92nd percentile; typical, unremarkable volume), which supports the view of an active infusion practice with both frequent evaluation visits and substantial chemo administration activity.

Tenure is long: the NPI was enumerated 2006-06-18 (~20 years ago), indicating an established provider record in Medicare billing. That duration combined with the concentration in high-cost oncology agents suggests a sustained specialty practice rather than a recent change in specialty or billing behavior.

Several codes show divergent peer standing that merit attention: 99213 is identified as "notably above typical national volume," indicating above-average office-visit billing intensity, while lower-percentile items such as J1439 (12.8K claims, $1 avg paid/claim, $12.8K revenue) rank #1094 of 1209 providers nationally (8th percentile; typical, unremarkable volume) and 74177 ranks #21888 of 23621 providers nationally (7th percentile; typical, unremarkable volume), both suggesting minimal relative activity in IV iron infusions and CT imaging compared with national peers. These contrasts underline that most Medicare revenue is driven by a narrow set of oncology infusions rather than a broad mix of supportive or diagnostic services.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

43 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	19,800	$40	$851.4K
J9299	Injection, nivolumab, 1 mg	19,440	$20	$466.6K
J9312	Injection, rituximab, 10 mg	2,260	$60	$144.6K
J9264	Injection, paclitaxel protein-bound particles, 1 mg	8,840	$10	$88.4K
J0897	Injection, denosumab, 1 mg	4,800	$20	$86.4K
Q5111	Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg	700	$110	$75.9K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	720	$90	$63.7K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	530	$120	$62.5K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	170	$130	$22.3K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	160	$130	$20.5K

Showing 1–10 of 43

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 43 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Alaska Distribution

Max Rabinowitz — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Alaska

Full comparison — all codes billed, vs. state median

43 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	2	10	13,300	$40	$609.5K
J9299	2	10	19,440	$20	$472.8K
J9312	3	10	2,330	$60	$168.4K
J0897	12	30	2,700	$20	$82.7K
J9264	1	10	7,570	$10	$75.8K
Q5111	2	10	700	$110	$71.7K
96413	4	20	230	$110	$30.2K
99214	378	1,210	90	$100	$16.2K
J1439	4	10	19,130	$1	$15.8K
74177	63	60	80	$110	$15.5K

Showing 1–10 of 43

Related Providers

Other providers that share a Tax Identification Number (TIN) with Max Rabinowitz, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Steven Liu	AK	Hematology & Oncology Physician	$3.4M	$0
Natalie Wallace	AK	Hematology & Oncology Physician	$1.2M	$0
Alaska Oncology And Hematology LLC	AK	Hematology & Oncology Physician	$0	$375.5K
Jeremy Rosiecki	AK	Physician Assistant	$97.2K	$0
Zach Zipsir	AK	Physician Assistant	$84.4K	$0

Nearby Providers

Other providers in the same ZIP code as Max Rabinowitz, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Alaska Native Tribal Health Consortium	AK	General Acute Care Hospital	$0	$397.1M
Providence Health & Services Washington	AK	General Acute Care Hospital	$0	$161.5M
Southcentral Foundation	AK	Community Health Clinic/Center	$0	$130.3M
Alaska Native Tribal Health Consortium	AK	Transportation Broker	$0	$65.5M
The Arc Of Anchorage	AK	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$50.8M
Good Samaritan Care Services	AK	In Home Supportive Care Agency	$0	$46.1M
Alaska Native Tribal Health Consortium	AK	General Acute Care Hospital	$0	$33.1M
Galen Hospital Alaska, Inc.	AK	General Acute Care Hospital	$0	$31.8M
Anchorage Community Mental Health	AK	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$31.7M
Patient Housing At Anmc	AK	General Acute Care Hospital	$0	$31M

Max Rabinowitz — Billing Profile & Reimbursement Data

Sign up for Max Rabinowitz — Billing Profile & Reimbursement Data policy alerts

Max Rabinowitz — Billing Profile & Reimbursement Data

Sign up for Max Rabinowitz — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References